Licensing status

Publication and contact information

Disease models

Bioluminescent mouse model of HPV+ oral tumors to track the effect of therapeutics

A bioluminescent mouse model of HPV+ oral tumors could help evaluate potential therapeutic candidates. In mice with inducible expression of the HPV oncogenes E6 transforming protein (human papillomavirus-16; HpV16gp1) and E7 transforming protein (human papillomavirus-16; HpV16gp2) and luciferase, oncogenic K-Ras (Kras) expression in the epithelia induced the development of oral tumors with enhanced bioluminescence that correlated with tumor growth. In the mouse model, rapamycin or image-guided radiotherapy induced tumor regression and decreased bioluminescence at least threefold compared with vehicle or no irradiation. Next steps could include using the model to test preclinical therapeutic candidates.
Rapamycin is a generic small molecule inhibitor of mammalian target of rapamycin (mTOR; FRAP; RAFT1).

SciBX 7(13); doi:10.1038/scibx.2014.381
Published online April 3, 2014

Patent and licensing status unavailable

Zhong, R. et al. Cancer Res.; published online Feb. 13, 2014;
Contact: Michael Spiotto, The University of Chicago, Chicago, Ill.